AIP to Acquire Avanos Medical for $1.27B in Healthcare Buyout

American Industrial Partners has agreed to acquire Avanos Medical, a publicly traded medical device manufacturer focused on pain management and digestive health, for approximately $1.27 billion. The all-cash deal values Avanos at $19.75 per share — a 28% premium to the stock's closing price on January 21 and the company's highest valuation since mid-2023.

The transaction represents a decisive pivot for Avanos, which has struggled to gain traction in public markets despite consistent revenue in the $700-750 million range and a portfolio of clinically differentiated products. For AIP, a New York-based private equity firm with $14 billion in assets under management, it's a bet that the company's operational challenges are solvable under private ownership — and that the pain management device market is poised for growth as chronic pain prevalence rises and opioid alternatives gain favor.

The deal, announced January 22, 2025, is expected to close in the second quarter pending shareholder and regulatory approval. Avanos will delist from the New York Stock Exchange and operate as a private entity within AIP's portfolio, which includes over 100 companies across industrial, healthcare, and services sectors.

What makes this notable isn't the purchase price — it's the strategic calculus behind it. Avanos hasn't been a broken business. It's been an overlooked one. The company's ON-Q Pain Relief System holds strong market share in post-surgical pain management, and its chronic care offerings — enteral feeding tubes, digestive health devices — serve sticky, recurring-revenue hospital and home care channels. But public market investors never rewarded the story, keeping the stock rangebound even as the business stabilized post-pandemic.

American Industrial Partners isn't a healthcare specialist — it's an industrial and services-focused firm with a track record of taking underperforming manufacturing and B2B businesses private, overhauling operations, and either growing them long-term or selling them at a markup. The firm's model is operational rather than financial engineering: buy companies with decent fundamentals and poor execution, fix the execution, capture the upside.

Avanos fits that profile cleanly. The company generates roughly $730 million in annual revenue with EBITDA margins in the mid-teens — respectable but not exceptional. It operates in two primary segments: Chronic Care (enteral feeding, urology, respiratory products) and Pain Management (ON-Q system, interventional pain devices). Both segments have defensible market positions, but neither has been a growth engine. Chronic Care has been flat to slightly declining; Pain Management has shown occasional growth but remains dependent on surgical volumes, which can be cyclical.

The thesis for AIP likely hinges on three operational levers. First, supply chain and manufacturing efficiency. Avanos has manufacturing footprint across multiple geographies and product lines; consolidation or automation could yield meaningful margin expansion. Second, commercial execution. The company's sales force and distribution strategy haven't been aggressive — there's room to push deeper into hospital systems and alternative care sites. Third, product development acceleration. Avanos has R&D capabilities but hasn't launched blockbuster products in years. Under private ownership, the company can invest with a longer time horizon and less quarterly earnings pressure.

None of these are revolutionary. But they're the kind of blocking-and-tackling improvements that private equity excels at when public markets won't pay for the journey from "fine" to "good."

Shareholders will receive $19.75 in cash for each share of Avanos common stock. That's a 28.3% premium to the January 21 close of $15.39, and a 36.5% premium to the 30-day volume-weighted average price leading up to the announcement. The total enterprise value, including net debt, comes to approximately $1.272 billion.

The premium is meaningful but not extravagant by recent healthcare M&A standards. In comparable med-tech take-privates over the past 24 months, premiums have ranged from 25% to 45%, depending on growth profile and competitive dynamics. Avanos sits on the lower end, reflecting its mature, slow-growth profile. The company's board unanimously approved the deal, and management — including CEO Joe Woody — has endorsed it publicly.

No competing bids have emerged publicly, though the announcement notes that Avanos conducted a "thorough review of strategic alternatives" before agreeing to the AIP offer. That language typically signals the company shopped itself and AIP was the highest (or only) credible bidder. Given the stock's lackluster performance and the premium on offer, shareholder approval is likely — though activist investors or opportunistic funds could surface if they believe a higher price is achievable.

Financing for the deal will come from AIP's Capital Fund IX, the firm's latest flagship vehicle, which closed at $4.5 billion in 2023. The firm is also arranging debt financing, though terms haven't been disclosed. At the announced valuation, leverage is likely in the 4-5x EBITDA range — standard for a stable, cash-generative healthcare business.

BofA Securities is serving as financial advisor to Avanos, with Wachtell, Lipton, Rosen & Katz as legal counsel. AIP is represented by Kirkland & Ellis on legal matters.

The 28% premium sounds attractive on the surface, but context matters. Avanos traded above $30 per share as recently as 2022, and the stock hit $40+ in 2018 before a series of operational missteps and market headwinds drove it down. Shareholders who bought at those levels are still underwater — the deal offers an exit, but not a recovery. Long-term holders are effectively crystallizing years of underperformance rather than betting on a turnaround.

Avanos's flagship product, the ON-Q Pain Relief System, is a continuous peripheral nerve block device used primarily in post-surgical settings. It delivers local anesthetic directly to the surgical site, reducing the need for systemic opioids. The device has been on the market for over two decades and is well-established in orthopedic, general surgery, and obstetric procedures.

The market for non-opioid pain management has been growing steadily as hospitals and payers seek alternatives to narcotics amid the ongoing opioid crisis. However, the space is also increasingly competitive. Devices like nerve stimulators, cryotherapy systems, and newer regional anesthesia platforms are all vying for share. ON-Q remains a trusted option, but it hasn't been a growth driver — volumes are tied to surgical activity, which has been uneven post-pandemic.

The broader pain management device market is projected to grow at a 6-8% CAGR through 2030, driven by aging populations, rising chronic pain prevalence, and regulatory tailwinds favoring opioid alternatives. That's a favorable backdrop, but Avanos hasn't captured a disproportionate share of that growth. AIP's bet is likely that better execution — more aggressive hospital contracting, expanded clinical evidence, new product iterations — can reverse that trend.

The Chronic Care segment, meanwhile, is a classic "annuity" business: high recurring revenue from consumable products (feeding tubes, urology products), strong hospital and home care relationships, but limited pricing power and exposure to reimbursement pressures. It's stable but not exciting. Private equity loves stable.

One open question is whether AIP will pursue tuck-in acquisitions to bolster the portfolio. The firm has historically been an active acquirer once it owns a platform — building out capabilities through add-ons rather than just optimizing what it bought on day one. In Avanos's case, bolt-on targets could include adjacent chronic care devices, specialty surgical products, or even services businesses that complement the device sales motion.

Avanos competes in fragmented markets. In pain management, peers include SPR Therapeutics (nerve stimulation), Pacira BioSciences (long-acting local anesthetics), and larger players like Medtronic with broad pain portfolios. In chronic care, it's up against Halyard Health (now owned by Owens & Minor), Cardinal Health, and private-label suppliers.

None of these competitors is dominant, and none has Avanos's specific mix of assets. That's both a strength — differentiation — and a weakness — no clear path to scale leadership in any single category. AIP will need to decide whether to sharpen focus (divest slower segments, double down on winners) or diversify further through M&A.

American Industrial Partners isn't a household name in healthcare private equity — firms like KKR, Warburg Pincus, and Advent dominate that space. But AIP has done healthcare deals before, typically in the medical products and services niches rather than high-growth biotech or digital health.

Recent healthcare investments include industrial hygiene and safety services companies, medical supply distributors, and niche device manufacturers. The firm's approach is consistent: buy overlooked, operationally improvable businesses in unglamorous categories, run them better, hold for 5-7 years, exit. It's worked well in industrial services and manufacturing; the model is directly applicable to a company like Avanos.

The firm's typical playbook involves bringing in experienced operators as CEOs or operational partners, implementing lean manufacturing principles, consolidating facilities, and professionalizing sales and marketing. Expect some version of that here. Joe Woody, the current CEO, hasn't been announced as staying or leaving — that's often a tell. If AIP brings in a new leader, it signals a fresh operational mandate. If Woody stays, it suggests continuity with a tighter mandate.

One risk worth flagging: AIP's industrial focus means it may not have deep relationships with hospital systems, GPOs, or payers — the key customer and reimbursement gatekeepers in medical devices. If the firm leans too heavily on manufacturing efficiency and underinvests in commercial strategy, the deal could underperform. Avanos's products are good, but they require sophisticated selling into complex healthcare procurement systems. That's not the same as selling industrial components to OEMs.

AIP typically holds portfolio companies for 5-7 years. Possible exit paths for Avanos include a sale to a larger medical device company (Medtronic, Stryker, or a diversified player looking to add pain or chronic care assets), a secondary buyout to another private equity firm, or — less likely given the operational thesis — a return to public markets via IPO.

The most probable path is a strategic sale. If AIP can demonstrate margin improvement, revenue stabilization, and a clearer growth narrative, the company becomes an attractive tuck-in for a larger player. The ON-Q franchise alone could be worth a premium to the right buyer with an existing acute pain or anesthesia business.

The deal requires approval from Avanos shareholders (expected to pass given board backing and the premium), Hart-Scott-Rodino antitrust clearance (low risk given no competitive overlap), and customary regulatory consents. No foreign regulatory reviews are flagged, suggesting AIP isn't a foreign buyer or the transaction doesn't trigger CFIUS or similar processes.

Closing is targeted for Q2 2025, implying a 3-4 month timeline. That's standard for a clean buyout with no complex approvals. Avanos has committed to a $48 million termination fee if the company backs out to accept a superior proposal, and AIP has committed to a $96 million reverse termination fee if financing falls through or the deal fails to close for reasons within AIP's control.

The reverse termination fee is double the Avanos fee, which is typical but worth noting — it protects Avanos shareholders if AIP's financing evaporates or the buyer gets cold feet. Given AIP's track record and committed capital, financing failure is unlikely unless credit markets seize up between now and close.

One wildcard: could another bidder emerge? It's possible but not probable. If a strategic buyer saw enough value to top $19.75, they likely would have bid during the "thorough review" process Avanos conducted before signing with AIP. Private equity firms could theoretically jump in, but the 36.5% premium to the 30-day VWAP leaves limited room for a topping bid unless someone sees radically different value creation potential.

The Avanos deal fits a broader pattern: private equity remains highly active in healthcare, but it's shifting away from high-multiple growth assets and toward undervalued, cash-generative businesses that public markets have left behind. With interest rates elevated and exit multiples compressed, PE firms are hunting for value rather than growth — and public med-tech companies trading below historical averages are prime targets.

Avanos isn't the first med-tech take-private in the past year, and it won't be the last. Similar dynamics are playing out across the sector: mature device companies with defensible products, recurring revenue, and margin improvement potential — but no compelling public market narrative — are being re-priced for private ownership. The question is whether these deals generate returns through operational improvement or simply through multiple arbitrage (buying low, selling higher to a strategic in a few years).

For Avanos specifically, the answer depends on execution. If AIP can drive margin expansion, stabilize revenue, and either launch new products or make smart acquisitions, the company could be worth significantly more than $1.27 billion in five years. If not, it'll be a case study in overpaying for a melting ice cube.

The broader trend to watch: how many other overlooked public med-tech companies are in AIP's crosshairs — or those of firms running the same playbook. If you're a $500M-$2B revenue medical device company with stable but unexciting growth, trading at 10-12x EBITDA, and struggling to get investor attention, you might be next.

This deal doesn't change the medical device landscape overnight. But it's a data point worth tracking — not because Avanos is uniquely important, but because the logic behind the deal is broadly applicable across a cohort of similar companies. AIP just made a bet that operational discipline can unlock value where public market patience couldn't. Whether that bet pays off will take years to know. For now, shareholders get their premium, AIP gets its platform, and the rest of us get a reminder that in private equity, "boring" is often a compliment.

Several things remain unclear and will become clearer in the months ahead. First, will AIP retain Avanos's current executive team, or bring in a new CEO and C-suite? The press release is silent on management continuity, which usually means it's still being negotiated or hasn't been finalized.

Second, what's the manufacturing and supply chain strategy? Avanos has facilities in multiple countries. Will AIP consolidate, automate, or offshore more production? Those decisions will determine margin trajectory and also signal how aggressive the firm is willing to be on operational restructuring versus maintaining product quality and delivery reliability.

Third, what's the M&A appetite post-close? AIP has historically been a serial acquirer within platforms. If the firm views Avanos as a pain management or chronic care roll-up vehicle, expect add-on deals within 12-18 months of close. If the plan is pure organic improvement, the strategy is lower-risk but also lower-upside.

And finally, what happens to R&D? Avanos has a pipeline of next-gen pain and digestive health products in development. Will those get accelerated, shelved, or spun out? Private ownership can allow longer development timelines without quarterly earnings pressure — or it can force ruthless prioritization and kill anything that doesn't hit aggressive ROI hurdles. Which version of PE ownership Avanos gets will matter enormously for the company's long-term competitiveness.